AroCell AB (publ) signs Letter of Intent with Korean-based company, Green Cross Cell Corporation. The companies have agreed to enter into a collaboration for the clinical development of TK 210 ELISA as a complementary biomarker related to Green Cross Cell's therapeutic products and methods and distribution rights for AroCell TK 210 ELISA. The TK 210 ELISA test measures TK1 protein levels for valuable information about the condition of cancer patients. The test may provide important information for
the prognosis and optimization of treatment strategy.